You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

19 Results
Drug
Other Name(s): Nexavar®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2023
Drug
Other Name(s): Vesanoid®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Drug
Other Name(s): Thalomid®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Drug
Other Name(s): Sutent®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2023
Drug
Other Name(s): Mekinist®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2021
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - Unresectable or metastatic/recurrent Gastrointestinal Stromal Tumour, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
SUNItinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2020
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    SORAfenib - Advanced hepatocellular carcinoma, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
SORAfenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - Metastatic renal cell carcinoma, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
SUNItinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2020
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    SORAfenib - Metastatic renal cell carcinoma of clear cell histology as second-line treatment, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
SORAfenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2020
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumours (pNET), according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
SUNItinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2024
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
  • trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trametinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2021
Drug
Other Name(s): Lonsurf®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024

Pages